Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
New angiogenesis research from J.J. Patard and co-researchers described
April 22nd, 2008
According to recent research published in the journal European Urology Supplements, "Metastatic renal cell carcinoma (mRCC) is largely resistant to conventional chemotherapy, hormonal therapy, and cytokine therapy and is associated with a poor prognosis. The European Association of Urology (EAU) recently published updated guidelines, with specific recommendations for treating mRCC." "The EAU recommendations were based on recent clinical study data, which demonstrated the superiority of newer targeted therapies over interferon-alpha (IFN-alpha). mRCC is a highly vascularised tumour, characterised in the majority of cases by over-production of angiogenic peptides...
Source: Cancer Weekly (2008-04-22)
|
